Valeant Pharma (VRX) Reports Q3 EPS of $0.14; Boosts FY15 EPS Outlook
Valeant Pharma (NYSE: VRX) reported Q3 EPS of $0.14, versus $0.81 reported last year. Revenue for the quarter came in at $2.79 billion, versus $2.06 billion reported last year.
"Today, we reported yet another consecutive quarter of strong financial results that exceeded expectations," stated J. Michael Pearson, chairman and chief executive officer. "I am incredibly proud of the hard work and effort put forth by Valeant's employees around the world. I would also like to thank all the doctors who prescribe our products and the patients who use them. We will be discussing our outperformance on our conference call later today, as well as addressing the most frequently asked questions we have been hearing from our shareholders. With our strong product portfolio and growth prospects, we feel very confident in our future outlook and we are reaffirming our $7.5 billion EBITDA floor for 2016."
Guidance:
Valeant Pharma sees Q415 EPS of $4.00 - $4.20, versus prior guidance of $3.98 - $4.18.
Valeant Pharma sees FY2015 EPS of $11.67 - $11.87, versus prior guidance of $11.50 - $11.80.
For earnings history and earnings-related data on Valeant Pharma (VRX) click here.